about
DNA Methylation-Based Classifier for Accurate Molecular Diagnosis of Bone SarcomasIdentifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid TumorsImpact of Variable RNA-Sequencing Depth on Gene Expression Signatures and Target Compound Robustness: Case Study Examining Brain Tumor (Glioma) Disease ProgressionClinical Use of Precision Oncology Decision SupportMegakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant MesotheliomaClinical Utility of Rapid Genotyping in Advanced Lung CancerParental Perspectives on Whole-Exome Sequencing in Pediatric Cancer: A Typology of Perceived UtilityMolecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in CholangiocarcinomaTranscriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapyMajority of -Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-HighHarnessing Clinical Sequencing Data for Survival Stratification of Patients with Metastatic Lung AdenocarcinomasRationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyDetection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive DiseaseepiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate CancerComprehensive Analysis of the Unfolded Protein Response in Breast Cancer SubtypesDuodenal-Jejunal Flexure GI Stromal Tumor Frequently Heralds Somatic NF1 and Notch Pathway MutationsClinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate CancerDose modification for safe treatment of a compound complex heterozygous DPYD variant carrier with 5-fluorouracilInitiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine StudyNext-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical ModelsImpact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung CancerReturning Individual Genetic Research Results to Research Participants: Uptake and Outcomes Among Patients With Breast CancerAcquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function MutationsPersonalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor BoardResponse and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1Patients' Medical and Psychosocial Experiences After Detection of a CDH1 Variant With Multigene Panel TestingIdentification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic SequencingStromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic AdenocarcinomaGenetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) CExpanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutationsLow Abundance of Circulating Tumor DNA in Localized Prostate CancerProlonged Partial Response to Bevacizumab and Valproic Acid in a Patient With GlioblastomaExceptional Chemotherapy Response in Metastatic Colorectal Cancer Associated With Hyper-Indel-Hypermutated Cancer Genome and Comutation of POLD1 and MLH1Active Disclosure of Secondary Germline Findings to Deceased Research Participants' Personal Representatives: Process and OutcomesDetection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid TumorsSurvival Outcomes by TP53 Mutation Status in Metastatic Breast CancerDiscussion of Trial Designs for Biomarker Identification and Validation Through the Use of Case StudiesDetection of Three Distinct Clonal Populations Using Circulating Cell Free DNA: A Cautionary Note on the Use of Liquid BiopsyRucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
P1433
Q56889019-D4854661-AA0A-4A11-A24F-00D338795608Q57216049-9B1C88C3-3A51-4BDE-9DFA-64D6969320F8Q57493525-FB3FBF6F-A521-4812-A9D7-F2F05BE96E48Q57498783-921F456F-B42B-4F30-ADCE-DB556F0C525AQ58132938-07A569FB-C328-4DE5-BC33-7CF57F031F3CQ58132942-3CD37B89-31A2-4A7D-8CDC-B28840E6429CQ58860482-534D397A-3510-4C62-90A8-3503609A30B9Q61917749-D77560F1-A854-4325-9AE4-0ED11AEDD06FQ63883997-7C2C7A74-86A1-462E-9121-C59AA901F4B4Q64068659-18047B89-A950-4ACD-8D9E-9CAC8401A9F5Q64107863-3F228FF9-6AE5-4844-B53D-0A38F6A0AC1AQ64119002-DFD5FF01-EEE6-4083-8301-423AB3A6E886Q64255946-5C1FED2F-FD13-4992-8B9B-0BA13044C4FAQ64265726-9CB98F5B-7CEB-45F9-AF59-F50907E26CEDQ89058295-4F33B936-3AE0-475D-9B41-DEA14EA3B68CQ89227772-5438EF91-4A81-4CD1-B212-832B5455A187Q89389462-59AA63EC-3BAE-4407-9A8D-80E6D92A427DQ89623884-D33FFA45-969F-4CCF-BC1A-32398A5DEFEFQ89765536-4DACD5D4-D417-4585-AC96-19D0DAA19B28Q89870003-DCBFEAF6-1CA9-4879-BA05-E8A60073985FQ89870006-45C0A85A-06C0-4C27-8295-B320670064F3Q89870010-CFE699FE-1C16-4553-8F4D-05955D8B2394Q89870343-B96DA116-EDEA-46BA-BAFB-670D3495F4A9Q90005545-F2262088-C3DD-441D-B4B3-E9AEB9C833CEQ90017809-95AD3005-2A84-4EAD-837A-3664D9FDFD04Q90057590-3AA5916B-4118-4F7B-B563-255517AA688DQ90070074-1F1F9DFC-59FC-4A1F-8A33-75E49AB6767DQ90070075-C61D7D6F-47FC-406A-A1A9-BB12EC219B2AQ90085098-45AB2804-6CC7-4918-A104-09C87634569CQ90089832-E46D9642-F4FF-4618-B8C2-22C30915272DQ90089836-22B69D0B-9A56-41E8-8127-4A09DBE6DE50Q90139206-97C12311-CD68-4F7E-AA92-0CDBBBF59245Q90207598-7BF7D5F5-5FB9-46E0-9909-7810C9AA62B5Q90225483-A5DA4D0F-6F5A-4D05-A2ED-203E7DDAEBE4Q90268371-99D2971A-591C-4EA6-AD15-2D2A1EC9643DQ90354804-29E7C659-2A52-418F-A15D-9CB723BAC43AQ90407961-CF783FAD-2202-4894-84BC-C0FA76BEAB88Q90452339-8A47072E-03B3-400C-84E1-ABF706A55C38Q90537861-BB9BE246-FFEC-48C3-85AF-73F53926585DQ90547590-245F851D-DDCE-4E93-8E77-4DDB1311DD23
P1433
description
online medical journal
@en
name
JCO Precision Oncology
@en
type
label
JCO Precision Oncology
@en
altLabel
JCO PO
@en
JCO Precis Oncol
@en
prefLabel
JCO Precision Oncology
@en
P243
P1055
P1476
JCO Precision Oncology
@en